Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

21 sept. 2012 08h00 HE | Source: Lumos Pharma, Inc.

NewLink Announces an Investigator Initiated Phase 2 Study of Sipuleucel-T Plus Indoximod in the Treatment of Certain Men With Advanced Prostate Cancer

AMES, Iowa, Sept. 21, 2012 (GLOBE NEWSWIRE) -- NewLink Genetics (Nasdaq:NLNK) announced today that it will begin an investigator initiated, randomized, double blind placebo controlled Phase 2 study...
20 sept. 2012 08h15 HE | Source: Lumos Pharma, Inc.

NewLink CEO to Participate in Panel Entitled "Innovation in Immunotherapy and Vaccines"

AMES, Iowa, Sept. 20, 2012 (GLOBE NEWSWIRE) -- NewLink Genetics (Nasdaq:NLNK) announced today that Dr. Charles Link, Chairman and CEO, will participate in a panel discussion entitled "Innovation in...
14 août 2012 08h00 HE | Source: Lumos Pharma, Inc.

NewLink Genetics Corporation Reports Second Quarter 2012 Financial Results

AMES, Iowa, Aug. 14, 2012 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (Nasdaq:NLNK), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today...
19 juin 2012 09h00 HE | Source: Lumos Pharma, Inc.

NewLink Updates Enrollment Information for Its Pivotal Phase 3 HyperAcute(R) Pancreas Immunotherapy (algenpantucel-L) Trial

AMES, Iowa, June 19, 2012 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (Nasdaq:NLNK) today announced that in the second quarter of 2012 it passed the midpoint in enrollment in its Phase 3...
04 juin 2012 12h00 HE | Source: Lumos Pharma, Inc.

Data From Phase 1 and Phase 1B Studies of NewLink Genetics' IDO Pathway Inhibitor (NLG8189) Presented at 2012 ASCO Annual Meeting

AMES, Iowa, June 4, 2012 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (Nasdaq:NLNK) today announced that data from Phase 1 and Phase 1B studies evaluating NLG8189 (D-1MT, 1-methyl-D-tryptophan or...
04 juin 2012 10h00 HE | Source: Lumos Pharma, Inc.

NewLink Genetics HyperAcute(R) Lung (tergenpumatucel-L) Immunotherapy Demonstrates a Correlation Between Immune Response and Survival in Patients With Non-Small Cell Lung Cancer

AMES, Iowa, June 4, 2012 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (Nasdaq:NLNK) announced its HyperAcute® Lung (tergenpantucel-L) immunotherapy will be featured today in a poster...
04 juin 2012 08h30 HE | Source: Lumos Pharma, Inc.

NewLink Genetics Reports Two- and Three-Year Overall Survival Data From Its Phase-2 HyperAcute(R) Pancreas (algenpantucel-L) Immunotherapy Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting

AMES, Iowa, June 4, 2012 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (Nasdaq:NLNK) announces that its HyperAcute® Pancreas (algenpantucel-L) Immunotherapy will be featured today in a poster...
01 juin 2012 09h00 HE | Source: Lumos Pharma, Inc.

Data From an Investigator-Initiated Phase 2 Study of NewLink Genetics' HyperAcute(R) Melanoma Immunotherapy Published in 2012 ASCO Annual Meeting Abstracts

AMES, Iowa, June 1, 2012 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (Nasdaq:NLNK) today announced results from a Phase 2 investigator-initiated study of NewLink's HyperAcute® Melanoma...
30 mai 2012 08h01 HE | Source: Lumos Pharma, Inc.

NewLink Genetics to Present at the Jefferies 2012 Global Healthcare Conference

AMES, Iowa, May 30, 2012 (GLOBE NEWSWIRE) -- NewLink Genetics (Nasdaq:NLNK) announced today that Dr. Charles Link, Chairman and Chief Executive Officer, will present at the Jefferies 2012 Global...
22 mai 2012 09h00 HE | Source: Lumos Pharma, Inc.

Data From NewLink Genetics Phase 2 Trial of Its HyperAcute(R) Pancreas (Algenpantucel-L) Immunotherapy to be Presented at the 2012 Digestive Disease Week

AMES, Iowa, May 22, 2012 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (Nasdaq:NLNK), today announced that Phase 2 data from its investigational HyperAcute® Pancreas immunotherapy clinical...

Page précédente